STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
Giacomo Canesin(Beth Israel Deaconess Medical Center), Rebecka Hellsten(Lund University)
Cited by 27
Related Papers
Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells
|Journal of Biological Chemistry|2014|91
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC‐like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
|The Prostate|2019|70
Scavenging of Labile Heme by Hemopexin Is a Key Checkpoint in Cancer Growth and Metastases
|Cell Reports|2020|63
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
|Cancer Immunology Immunotherapy|2021|33